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Abstract 
Background: Mosaic chromosomal alterations (mCAs) are large chromosomal gains, losses and copy‑neutral losses 
of heterozygosity (LOH) in peripheral leukocytes. While many individuals with detectable mCAs have no notable 
adverse outcomes, mCA‑associated gene dosage alterations as well as clonal expansion of mutated leukocyte clones 
could increase susceptibility to disease.
Results: We performed a phenome‑wide association study (PheWAS) using existing data from 482,396 UK 
Biobank (UKBB) participants to investigate potential associations between mCAs and incident disease. Of the 1290 
ICD codes we examined, our adjusted analysis identified a total of 50 incident disease outcomes associated with 
mCAs at PheWAS significance levels. We observed striking differences in the diseases associated with each type of 
alteration, with autosomal mCAs most associated with increased hematologic malignancies, incident infections and 
possibly cancer therapy‑related conditions. Alterations of chromosome X were associated with increased lymphoid 
leukemia risk and, mCAs of chromosome Y were linked to potential reduced metabolic disease risk.
Conclusions: Our findings demonstrate that a wide range of diseases are potential sequelae of mCAs and highlight 
the critical importance of careful covariate adjustment in mCA disease association studies.
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Introduction
Cells accumulate somatic mutations during normal 
growth and cellular division [36, 48], despite the presence 
of cellular mechanisms to prevent and repair genomic 
damage [19]. In many cases, acquired somatic mutations 
are not compatible with cellular survival resulting in 
apoptosis [9]. However, some mutations can evade repair 
mechanisms and are tolerated by cells [40, 48]. These 
surviving mutations could provide competitive advantage 
over normal cells lacking these somatic mutations. Clonal 
expansion of these cells result in genetic mosaicism, the 
presence of a clonal subset of cells with a mutation that 
differs from normal germline DNA [31, 43]. As mCAs 
generally cover an expansive genomic footprint (often 
more than 50 kilobases), these events offer opportuni-
ties to investigate future health outcomes that could arise 
due to a non-trivial fraction of the genome impacted by a 
somatic alteration [53].
Peripheral leukocytes are perhaps the most well-
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DNA is easy to obtain for large populations of indi-
viduals [14, 20, 23, 28, 29, 34, 42, 46]. Clonal hemat-
opoiesis (CH) is an age-related process in which a 
hematopoietic stem cell which has acquired a somatic 
mutation, passes that mutation onto daughter cells. 
The chance of observing these subclones carrying 
genomic alterations increases with increasing age. 
These daughter cells eventually form a clonal sub-
population of cells with the somatic mutations offering 
potential cellular survival advantages. Genomic altera-
tions can range in size from a single base pair change 
(e.g., somatic SNVs) [16, 21, 22], to very large struc-
tural mosaic chromosomal alterations (mCAs) [20, 23, 
28, 29, 34, 37, 42, 46]. mCAs can be divided into dif-
ferent categories according to the location and span 
of these events, i.e. telomeric, centromeric, intersti-
tial, and whole chromosome. Additionally, copy num-
ber changes can be used to classify these alterations 
as mosaic chromosomal gains, mosaic chromosomal 
losses, and mosaic chromosomal losses of heterozygo-
sity (LOH) [34].
Mosaic loss of the Y chromosome (mLOY) is the 
most frequently occurring mCA in males [12, 20, 46, 
50, 56]. The frequency of mLOY increases with age, 
with < 2.5% of men below the age of 40 having detecta-
ble mLOY and estimated frequencies rapidly increasing 
in excess of 40% by 70 years of age [46, 56]. A number 
of studies have investigated the impact of mLOY on 
future health outcomes and noted possible associa-
tions with risk of solid tumors [13, 25, 26, 56], Alzhei-
mer’s disease [7], cardiovascular disease [18] and other 
chronic health outcomes [11, 17]. However, the level 
of evidence for these associations varies by study and 
some lack adjustment for key confounders like smoking 
patterns. Likewise, some studies of autosomal mosai-
cism have reported associations with risk of cancer; 
particularly hematologic cancers [20, 28], diabetes [1], 
and infectious disease [54]. Current investigation of 
phenotypes associated with mosaic loss of the X chro-
mosome (mLOX) in females is limited [33]. mLOX is 
not observed in males since it is critical male cells carry 
at least one copy of the X chromosome [55].
Herein, we perform a phenome-wide association 
study (PheWAS) of 1290 first occurrence of incident 
health conditions (both self-reported and a subset clini-
cally verified) among 482,396 UK Biobank (UKBB) par-
ticipants [44]. Our aim is to systematically scan for 
associations between risk of disease and presence of 
mCAs. Our approach has been to perform robust sta-
tistical adjustment, require stringent significance levels 
and carry out additional sensitivity analyses to identify 
a high-confidence set of incident disease associations to 
be prioritized in future studies of mCAs.
Methods
Study population
UK Biobank sample collection and processing proto-
cols are previously described [8]. In brief, UK Biobank 
enrolled approximately half a million participants, aged 
37 to 73, from 22 assessment centers across the UK from 
2006 to 2010. Participants provided informed consent for 
collection of medical histories using touch-screen ques-
tionnaires, participation in nurse-led interviews, and 
blood sample collection at enrollment. 4.5  mL of blood 
samples were collected in anticoagulant tubes containing 
acid citrate dextrose, EDTA, or lithium-heparin as well 
as silica-containing tubes for fast clotting. Upon arrival 
at the central processing laboratory, blood was aliquoted 
and cryopreserved at − 80 °C or in liquid nitrogen within 
24 h.
Genotyping and detection of mosaicism
DNA extracted from the blood samples was genotyped 
on the Applied Biosystems UK BiLEVE or UK Biobank 
Axiom array. After removing individuals with sex dis-
cordance or whose DNA failed QC during genotyping, 
482,396 individuals with genotype and phenotype data 
were included for analyses. We used previously generated 
data on copy number variation and corresponding cellu-
lar fraction [28, 29]. Additional steps designed for detect-
ing mosaic Y loss events were performed as described 
previously [46]. In brief, log transformed intensities from 
UK Biobank genotyping arrays were used to yield  log2 R 
ratio and B-allele frequency for each SNP, and the Eagle2 
software [27, 30] was employed to phase SNPs. After 
phasing, a hidden Markov model was employed to detect 
allelic imbalances using additional information from 
long-range haplotype data. Chromosome Y events were 
detected using B-allele frequency in two pseudo-auto-
somal regions (PAR) shared between the Y and X chro-
mosomes, and further examination of  log2 R ratio across 
the whole chromosome was employed to determine copy 
number changes [46].
Phenotypes
First occurrence of 1764 ICD-10-coded diseases (UK 
Biobank category 1712) were derived from linkage to pri-
mary care, hospital admission, cancer registry, death reg-
ister data as well as self-report disease history obtained 
at enrollment. We further combined these data with the 
most up-to-date inpatient data (UK Biobank fields 41270 
and 41280) as well as cancer registry data (UK Biobank 
fields 40005 and 40006). For the main PheWAS [2, 6] 
analysis, we first investigated incident cases defined by 
diagnoses occurring after enrollment; for simplicity 
in performing the PheWAS, individuals with diseases 
diagnosed before enrollment were coded as controls. 
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To ensure that this control coding scheme did not bias 
reported associations, sensitivity analyses by cancer 
status and additional adjustment for ancestry as well 
as Mendelian randomization were performed. Further 
exploratory analyses focused on prevalent disease and 
medication codes to more comprehensively examine 
associations with mCAs.
Medications
The UK Biobank has 6745 unique medication codes (UK 
Biobank category 20003) derived from the Read Codes, 
Clinical Terms Version 3 (CTV3). As prior publications 
curating UK Biobank medications were incomplete [51] 
or based on text interpreters (Categorising UK Biobank 
Self-Reported Medication Data using Text Matching 
[3]), we traced the origins of each UK Biobank medi-
cation code back to the original CTV3 Read Codes to 
assign standardized active ingredients to each code. All 
UK Biobank medication codes were converted with high 
fidelity (100%) to 6197 unique CTV3 Read Codes along 
with hierarchy-path information to 1073 single ingre-
dients and assigned Unified Medical Language System 
(UMLS) RxNorm codes using the “RxNormR” pack-
age in R. RxNorm codes provided connections to other 
medication classification systems including ATC (WHO), 
DrugBank (University of Alberta and the Metabolomics 
Innovation Centre) and MeSH (NLM thesaurus). In some 
cases, manual edits were required to provide missing 
ATC codes and exclude codes that did not apply based 
on CTV3 path information. Finally, PheWAS analysis of 
mCAs was performed on the reported medications using 
each of the five levels of ATC codes: chemical substance, 
chemical subgroup, pharmacological subgroup, thera-
peutic subgroup, and anatomical main group to identify 
certain components of medications that may be associ-
ated with mCAs.
Statistical analyses
All statistical analyses were performed in R version 4.0.3 
[41]. PheWAS was performed using the “PheWAS” pack-
age [2]. Variables adjusted in the PheWAS models include 
age,  age2, sex (for analyses other than loss of X or Y chro-
mosomes), and a detailed 25-level smoking variable. The 
detailed 25-level smoking variable was created as previ-
ously described [25] and includes information on smok-
ing intensity, duration and tobacco type. Genetic ancestry 
proportions were calculated using SNPweights [4], which 
utilizes SNP weights computed from large reference pan-
els to infer genetic ancestry. The percentage of European, 
African, and Asian ancestry were computed for each 
participant, and these percentages were used in adjusted 
analyses. Phenome-wide significance levels were calcu-
lated by Bonferroni correction (0.05/number of diseases 
tested), in which the number of diseases tested vary by 
the category of genomic alteration investigated. We set a 
minimum number of cases for inclusion in analyses of 20 
to perform reliable asymptotic association tests. In total, 
autosomal mCA models with participants of both sexes 
had 1290 incident diseases with sufficient case numbers, 
mLOY models with males had 1140 incident diseases, 
and mLOX models with females included 1128 incident 
diseases. Manhattan plots for the PheWAS were created 
with the “ggplot2” package [49].
We utilized the “GLIDE” package to test potential plei-
otropy [5] and applied the Steiger filter to remove mLOY-
related SNPs which could be subject to reverse causation 
from either body mass index or high blood sugar. With 
a false discovery rate threshold of 0.05, 127 out of 156 
previously published mLOY-related SNPs [46] were cho-
sen as the mLOY instrument. Mendelian randomization 
analyses were conducted with the “MendelianRandomi-
zation” package [52].
Results
Detectable mCAs in the UK Biobank population
A total of 482,396 individuals were examined for mCAs, 
with a total of 17,113 (3.5%) having at least one detect-
able autosomal event and a total of 19,632 mosaic chro-
mosomal alterations detected on the autosomes. Of the 
detected autosomal events, 8185 (41.7%) were copy num-
ber neutral, 3718 (18.9%) were losses, 2389 (12.2%) were 
gains, and 5341 (27.2%) had undetermined copy number 
state due to challenges with assigning copy number sta-
tus to events with a low cellular fraction of affected cells 
(Additional file  1: Fig. S1). In addition to mosaic events 
of the autosomes, we also identified 43,297 males (19.6%) 
with mosaic chromosome Y loss (mLOY) and 12,550 
females (4.8%) with chromosome X loss (mLOX). There 
were no cases of mLOX detected in males.
Observed associations between mosaic chromosomal 
alterations and incident disease
We first performed a PheWAS for incident diseases 
that were captured in the UKBiobank resource (Table 1, 
Fig. 1a). We observed the strongest association between 
autosomal mCAs and risk of C91 lymphoid leukemia (OR 
23.74, p < 5 ×  10–324). In addition to lymphoid leukemia, 
we also observed a strong association with C83 diffuse 
non-Hodgkin’s lymphoma (OR 4.62, p = 9.64 ×  10–66). 
However, lymphoid lineage malignancies were not the 
only hematologic malignancy associated with autoso-
mal mCAs; diseases of the myeloid lineage were also 
found to be associated, including D45 polycythaemia 
vera (OR 12.26, p = 3.37 ×  10–61), D46 myelodysplastic 
syndromes (OR 6.19, p = 1.65 ×  10–39), and C92 myeloid 
leukemia (both acute C92.0 and chronic C92.1 myeloid 
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Table 1 Statistically significant associations for mCAs and incident disease associations.
mCA Disease N Percent with 
preceding 
cancer




Autosome C91 Lymphoid leukaemia 616 35.47 23.74 [20.21–27.88] < 5 ×  10–324
Autosome D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haemat‑
opoietic and related tissue
729 37.5 5.29 [4.38–6.39] 1.97 ×  10–67
Autosome C83 Diffuse non‑Hodgkin’s lymphoma 903 50.67 4.62 [3.88–5.5] 9.64 ×  10–66
Autosome D45 Polycythaemia vera 201 21.47 12.26 [9.1–16.51] 3.37 ×  10–61
Autosome C85 Other and unspecified types of non‑Hodgkin’s lymphoma 859 59.02 4.28 [3.56–5.15] 1.27 ×  10–53
Autosome D70 Agranulocytosis 4637 72.65 2.24 [2.02–2.49] 9.73 ×  10–51
Autosome D46 Myelodysplastic syndromes 302 47.86 6.19 [4.72–8.13] 1.65 ×  10–39
Autosome C92 Myeloid leukaemia 381 47.22 5.19 [4–6.73] 1.66 ×  10–35
Autosome R16 Hepatomegaly and splenomegaly, not elsewhere classified 611 36.33 3.78 [2.99–4.77] 9.44 ×  10–29
Autosome D69 Purpura and other haemorrhagic conditions 3090 38.04 2.01 [1.76–2.29] 2.02 ×  10–25
Autosome A41 Other septicaemia 10,144 52.41 1.54 [1.42–1.67] 2.43 ×  10–25
Autosome D80 Immunodeficiency with predominantly antibody defects 248 42.63 5.44 [3.91–7.56] 7.27 ×  10–24
Autosome D75 Other diseases of blood and blood‑forming organs 1059 25.52 2.77 [2.27–3.38] 9.33 ×  10–24
Autosome C95 Leukaemia of unspecified cell type 50 76.92 13.37 [7.43–24.06] 4.92 ×  10–18
Autosome D72 Other disorders of white blood cells 794 27.25 2.66 [2.1–3.36] 2.97 ×  10–16
Autosome J18 Pneumonia, organism unspecified 17,638 29.62 1.32 [1.24–1.41] 3.19 ×  10–16
Autosome C94 Other leukaemias of specified cell type 32 70.59 14.93 [7.2–30.96] 3.73 ×  10–13
Autosome D61 Other aplastic anaemias 879 46.57 2.24 [1.78–2.82] 6.94 ×  10–12
Autosome Z51 Other medical care 23,428 63.39 1.24 [1.16–1.32] 1.38 ×  10–11
Autosome C84 Peripheral and cutaneous T‑cell lymphomas 154 41.08 4.37 [2.83–6.72] 2.27 ×  10–11
Autosome C93 Monocytic leukaemia 51 80.77 6.61 [3.5–12.47] 5.89 ×  10–9
Autosome J90 Pleural effusion, not elsewhere classified 10,097 42.9 1.29 [1.18–1.41] 1.06 ×  10–8
Autosome C88 Malignant immunoproliferative diseases 121 69.7 4.17 [2.55–6.83] 1.43 ×  10–8
Autosome C82 Follicular [nodular] non‑Hodgkin’s lymphoma 347 37.96 2.71 [1.91–3.83] 1.94 ×  10–8
Autosome Z85 Personal history of malignant neoplasm 20,384 88.65 1.21 [1.13–1.29] 1.98 ×  10–8
Autosome J98 Other respiratory disorders 12,465 29.57 1.26 [1.16–1.37] 4.06 ×  10–8
Autosome Y43 Primarily systemic agents 2494 93.78 1.58 [1.34–1.86] 5.24 ×  10–8
Autosome B25 Cytomegaloviral disease 171 51.13 3.63 [2.27–5.81] 7.78 ×  10–8
Autosome N17 Acute renal failure 14,465 42.7 1.22 [1.13–1.32] 1.61 ×  10–7
Autosome E87 Other disorders of fluid, electrolyte and acid–base balance 15,028 38.77 1.22 [1.13–1.31] 2.40 ×  10–7
Autosome D64 Other anaemias 16,970 30.46 1.2 [1.11–1.29] 9.06 ×  10–7
Autosome Z94 Transplanted organ and tissue status 724 44.28 1.99 [1.5–2.65] 1.94 ×  10–6
Autosome D59 Acquired haemolytic anaemia 177 38.52 2.96 [1.85–4.73] 5.70 ×  10–6
Autosome R50 Fever of unknown origin 3504 48.62 1.4 [1.21–1.63] 6.79 ×  10–6
Autosome B96 Other bacterial agents as the cause of diseases classified to other chapters 9917 33.45 1.23 [1.12–1.35] 8.21 ×  10–6
Autosome R60 Oedema, not elsewhere classified 2075 42.78 1.49 [1.25–1.78] 1.11 ×  10–5
Autosome E83 Disorders of mineral metabolism 5293 43.15 1.3 [1.15–1.47] 2.23 ×  10–5
Autosome R22 Localised swelling, mass and lump of skin and subcutaneous tissue 1175 28.16 1.66 [1.31–2.11] 2.82 ×  10–5
Autosome G72 Other myopathies 258 28.99 2.45 [1.6–3.74] 3.29 ×  10–5
Autosome T86 Failure and rejection of transplanted organs and tissues 232 49.76 2.6 [1.65–4.08] 3.39 ×  10–5
mLOX C91 Lymphoid leukaemia 236 35.47 2.45 [1.7–3.53] 1.40 ×  10–6
mLOX J03 Acute tonsillitis 1167 4.97 1.78 [1.39–2.27] 4.85 ×  10–6
mLOY E11 Non‑insulin‑dependent diabetes mellitus 14,110 21.37 0.8 [0.77–0.84] 3.67 ×  10–22
mLOY I10 Essential (primary) hypertension 46,694 20.37 0.91 [0.89–0.94] 2.91 ×  10–11
mLOY H36 Retinal disorders in diseases classified elsewhere 1359 20.69 0.65 [0.56–0.75] 1.46 ×  10–9
mLOY E66 Obesity 12,647 22.40 0.87 [0.83–0.91] 1.12 ×  10–8
mLOY E14 Unspecified diabetes mellitus 1642 11.07 0.7 [0.61–0.8] 9.34 ×  10–8
mLOY M10 Gout 5601 14.55 0.87 [0.81–0.93] 3.74 ×  10–5
mLOY E16 Other disorders of pancreatic internal secretion 1641 30.03 0.78 [0.69–0.88] 4.28 ×  10–5
mLOY G63 Polyneuropathy in diseases classified elsewhere 646 29.78 0.65 [0.53–0.8] 4.29 ×  10–5
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Table 1 (continued)
Only PheWAS significant associations are reported (P < 3.88 ×  10–5 for autosomal, P < 4.43 ×  10–5 for mLOX, and P < 4.39 ×  10–5 for mLOY). All PheWAS associations are 
adjusted for age,  age2, smoking, and sex (only for autosomal mCA analyses). We define percent with preceding cancer as the percentage of individuals who have been 
diagnosed with any cancer prior to the diagnosis of that disease
Fig. 1 Manhattan plots of incident disease diagnoses and mCA 
in UKBB organized by disease category/anatomical location. All 
models are adjusting for age,  age2, detailed 25‑level smoking, and 
sex (only for autosomal mCA analyses). Upward closed triangles 
represent diseases with positive associations while downward open 
triangles represent diseases with negative associations. Colors are 
used to separate diseases in different ICD‑10 phenotype blocks. 
The red line represents the PheWAS significance level (Bonferroni 
correction: 0.05/number of diseases tested) and the blue dashed line 
represents the suggestive threshold (1/number of diseases tested). 
A maximum of the ten most significant medication codes above the 
suggestive threshold are labeled. PheWAS results are for: a Autosomal 
mCAs, 1290 diseases tested (PheWAS significance level: 3.88 ×  10–5, 
suggestive line: 7.75 ×  10–4); C91 Lymphoid leukaemia, C92 Myeloid 
leukaemia, C85 Other and unspecified types of non‑Hodgkin’s 
lymphoma, C83 Diffuse non‑Hodgkin’s lymphoma, D47 Other 
neoplasms of uncertain or unknown behaviour of lymphoid, 
haematopoietic and related tissue, D45 Polycythaemia vera, D69 
Purpura and other haemorrhagic conditions, D46 Myelodysplastic 
syndromes, D70 Agranulocytosis, and R16 Hepatomegaly and 
splenomegaly, not elsewhere classified. b mLOX, 1,128 diseases 
tested (PheWAS significance level: 4.43 ×  10–5, suggestive line: 
8.87 ×  10–4); C91 Lymphoid leukaemia, C83 Diffuse non‑Hodgkin’s 
lymphoma, J03 Acute tonsillitis, and M48 Other spondylopathies. c 
mLOY, 1140 diseases tested (PheWAS significance level: 4.39 ×  10–5, 
suggestive line: 8.77 ×  10–4); E11: Non‑insulin‑dependent diabetes 
mellitus, E14: Unspecified diabetes mellitus, E16: Other disorders of 
pancreatic internal secretion, E66: Obesity, H36: Retinal disorders in 
diseases classified elsewhere, I10: Essential (primary) hypertension, 
G63: Polyneuropathy in diseases classified elsewhere, L03: Cellulitis, 
M10: Gout, and N17: Acute renal failure
▸
leukemia; OR 5.19, p = 1.66 ×  10–35). This suggests that 
the association between mCAs and myeloid and lym-
phoid lineage diseases points towards an early pro-
genitor cell, leading to abnormal growth of distinct sets 
of blood cells. Additionally, we detected associations 
which could be partially attributed to cancer progres-
sion as well as treatment evidenced by simultaneous or 
prior diagnoses of neoplasm. Diagnoses included D70 
agranulocytosis (OR 2.24, p = 9.73 ×  10–51), A41 other 
septicaemia (OR 1.54, p = 2.43 ×  10–25), D80 immunode-
ficiency with predominantly antibody defects (OR 5.44, 
p = 7.27 ×  10–24), D61 other aplastic anemia (OR 2.24, 
p = 6.94 ×  10–12), J18 pneumonia of unspecified organ-
ism (OR 1.32, 3.19 ×  10–16), J90 pleural effusion (OR 1.29, 
p = 1.06 ×  10–8), B25 cytomegaloviral disease (OR 3.63, 
p = 7.78 ×  10–8), and T86 failure and rejection of trans-
planted organs and tissues (OR 2.60, p = 3.39 ×  10–5). 
When stratifying by cancer diagnoses prior to these 
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diseases, most effect estimates were higher in magnitude 
in people with a prior cancer diagnosis (Additional file 1: 
Table  S1); this is despite much larger variation in these 
strata due to smaller sample sizes. Sensitivity analyses 
with additional adjustment of genetic ancestry resulted 
in the same statistically significant findings in autosomal 
mCAs, except for C93 monocytic leukemia (Additional 
file  1: Table  S2). In this case, the model of monocytic 
leukemia failed to converge suggesting uneven ancestral 
distribution of monocytic leukemia among UK Biobank 
participants. PheWAS on each autosome found associa-
tions with a very similar set of diseases and demonstrated 
that blood organ malignancies were often associated with 
mCAs on multiple autosomes ( Additional file 1: Tables 
S3, S4).
For mLOX events in women, we found an increased 
risk of C91 lymphoid leukemia (OR 2.45, p = 1.40 ×  10–6) 
as well as an unrelated outcome, J03 acute tonsilli-
tis (OR 1.78, p = 4.85 ×  10–6) (Table  1, Fig.  1b). mLOY 
had an entirely different spectrum of disease associa-
tions from mLOX and autosomal mCAs. Not only was 
there an absence of an association with blood organ and 
tissue-related diseases, we observed protective associa-
tions between mLOY and a series of metabolic condi-
tions: E11 type II diabetes (OR 0.80, p = 3.67 ×  10–22), 
M10 gout (OR 0.87, p = 3.74 ×  10–5), E66 obesity (OR 
0.87, p = 1.12 ×  10–8), H36 retinal disorders (OR 0.65, 
p = 1.46 ×  10–9), and I10 primary hypertension (OR 0.91, 
p = 2.91 ×  10–11) (Table 1, Fig. 1c).
Examining the potential protective effects of mLOY 
with incident metabolic diseases
To investigate connections with a range of metabolic 
diseases, we performed additional analyses to better 
examine the impact of established common underlying 
confounders (e.g., prior cancer history or BMI). A sen-
sitivity analysis in a subset excluding individuals with 
prior cancer history, did not find evidence that prior his-
tory of cancer is a confounder in our study (Additional 
file 1: Table S5). However, adjustment for BMI completely 
attenuated most of the negative associations between 
mLOY and metabolic diseases. The retinal disorders 
(OR 0.65, p = 6.36 ×  10–8) and primary hypertension 
(OR 0.94, p = 1.35 ×  10–6) remained negatively associ-
ated after BMI adjustment, albeit with attenuated effect 
sizes (Additional file  1: Table  S6). We examined poten-
tial underlying causes of retinal diseases by investigating 
other comorbidities in the group of patients with incident 
retinal disease (n = 3752). Among individuals with retinal 
disorders, 3408 (90.8%) were diagnosed with non-insulin 
dependent diabetes, 3103 (82.7%) had primary hyperten-
sion, and 3073 (81.9%) had unspecified diabetes. In total, 
98.8% of all patients suffering retinal disorders had at 
least one of the three aforementioned diseases suggest-
ing the association of mLOY with retinal disease may be 
a result of these underlying conditions that predispose to 
retinal disease.
To further examine the observed protective association 
between Y loss and the two traits that remained signifi-
cant after BMI adjustment (hypertension and retinal dis-
eases), Mendelian randomization (MR) was performed 
on previously-reported germline variants associated 
with mLOY [46]. We used Steiger filter to remove SNPs 
which could be associated with mLOY through effects 
on hypertension or abnormal blood sugar (see Methods). 
Table 2 shows the effect estimates from the observational 
study and MR (IVW method). The Mendelian Randomi-
zation (MR) analyses for retinal diseases remained statis-
tically significant, and the MR effect estimate was in the 
same direction suggesting that mLOY could be an inde-
pendent protective factor for retinal disease, although 
further investigation is needed.
Exploratory analyses of mosaicism and prevalent disease
We also tested for associations between the three types 
of detectable mosaicism (autosomal, LOX, and LOY) and 
prevalent disease. We observed 39 phenome-wide signifi-
cant (Bonferroni corrected p < 3.88 ×  10–5) disease associ-
ations with autosomal mosaic events, 62 (p < 4.43 ×  10–5) 
disease associations with mLOX, and 149 phenome-
wide significant (p < 4.39 ×  10–5) disease associations 
with mLOY (Additional file 1: Table S7, Fig S2). Caution 
Table 2 Comparison of effect estimates between observational associations and Mendelian randomization (MR) estimates from 
inverse variance weighted (IVW) method.
Observational associations adjust for age,  age2, and 25-level smoking. MR estimates use selected variants previously identified to be associated with mLOY 
susceptibility (Thompson et al. [46])
Observation MR IVW
Trait Odds ratio [95% confidence 
interval]
P-value Odds ratio [95% confidence 
interval]
P-value
Retinal diseases 0.67 [0.58–0.77] 6.06 ×  10–8 0.77 [0.68–0.87] 4.49 ×  10–5
Hypertension 0.92 [0.89–0.96] 5.11 ×  10–10 0.99 [0.97–1.02] 0.175
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should be exercised in interpretation of these prevalent 
disease associations due to unknown timing of both the 
primary diagnoses and detectible mosaicism as well as 
the fact that important confounders were measured at 
study enrollment and might not reflect the status of par-
ticipants when diseases and mosaicism first occurred.
We observed several prevalent diseases that were asso-
ciated with mosaic events across autosomes and both 
sex chromosomes. The most frequently observed dis-
ease associations were in diseases related to prevalent 
cardiovascular or metabolic disease. A number of age-
ing-related conditions, like coxarthrosis, other arthrosis 
(M19 other arthrosis includes M19.0 primary arthrosis, 
M19.1 posttraumatic arthrosis, M19.2 other secondary 
arthrosis, and M19.8 other specified arthrosis, and M19.9 
unspecified arthrosis), osteoporosis without fracture, and 
spondylosis, were also associated with all forms of mosai-
cism. Other observed prevalent disease associations 
included contraceptive management, vasomotor and 
allergic rhinitis.
Prevalent conditions associated with both autoso-
mal mosaicism and mLOY in men included a history of 
malignant neoplasm, hyperplasia or neoplasm of pros-
tate, atherosclerosis, and inguinal hernia. In women, 
autosomal mCAs and mLOX were both negatively asso-
ciated with prevalent excessive, frequent and irregular 
menstruation.
A number of conditions shared between mLOY and 
mLOX were not associated with autosomal mCAs. Dis-
eases of the respiratory and digestive systems were the 
most frequently found to be positively associated with 
sex chromosome loss in both sexes. We also observed 
associations for sex chromosome loss with diseases in 
the urinary system, including chronic renal failure and 
unspecified hematuria.
Observed associations between mosaicism and medication 
ATC codes
UK Biobank participant medications were converted to 
WHO Anatomic Therapeutic Chemical (ATC) codes 
and screened for associations for mCAs at different 
ATC code levels. Figure 2 and Additional file 1: Table S8 
demonstrate that while we did not identify statistically 
significant associations between ATC level 3 medica-
tions and autosomal mCAs (p < 3.27 ×  10–4) or mLOX 
(p < 3.27 ×  10–4), mLOY (p < 3.27 ×  10–4) were shown 
to be negatively associated with blood glucose lowering 
drugs (OR 0.73, p = 4.24 ×  10–25), insulins and analogues 
(OR 0.78, p = 9.18 ×  10–6), as well as calcium channel 
blockers (OR 0.89, p = 2.42 ×  10–8), beta blockers (OR 
0.91, p = 4.29 ×  10–6), and antigout preparations (OR 
0.68, p = 1.25 ×  10–18). These results are consistent with 
the protective associations with incident diseases.
Discussion
In this study, we examined plausible associations 
between detectible mCAs and first occurrence of a range 
of diseases in a large, well-characterized population of 
approximately 500,000 individuals. We utilized existing 
high-confidence mosaic alteration calls [28, 29, 46] and 
created a comprehensive aggregation of first occurrence 
of diseases by integrating primary care, inpatient data, 
death registry, cancer registry as well as self-reported dis-
ease history obtained through interview at study enroll-
ment. Our analyses identified mCA-disease associations, 
many of which were associated with specific types of 
mCA, suggesting distinct mechanisms or perturbations 
of key pathways in their pathogenesis. Examination of 
potential confounders using sensitivity analysis and 
adjustment demonstrated the critical importance of care-
ful covariate adjustment in CH-disease association stud-
ies to avoid reporting spurious associations.
We observed robust evidence for known associations 
between autosomal mCAs and hematologic cancer risk. 
We observed the strongest associations with lymphoid 
malignancies, and also noted substantial evidence for 
myeloid malignancies. This suggests that autosomal 
mCAs predispose to cancer risk in both the lymphoid 
and myeloid compartments. Consistent with prior 
reports, we observed evidence for potential associations 
between autosomal mCAs and various blood organ-
related diseases as well as infections possibly linked to 
cancer treatment [54]. These findings indicate that clonal 
expansion of aberrant mCA clones can have an overall 
effect on select blood components that manifest in dis-
tinct detectable and diagnosable diseases. Such clonal 
expansion of autosomal mCAs could promote blood tis-
sue disease risk by reducing stem cell diversity, impact-
ing blood cell differentiation and altering leukocyte 
function due to copy-number or loss of heterozygosity 
(LOH) induced changes in gene regulation and expres-
sion. Similar to the autosomes, mLOX was associated 
with increased risk of lymphoid leukemia suggesting 
mLOX events may also predispose to hematologic can-
cer risk. Likewise, we observed an association between 
mLOX and acute tonsillitis indicating mLOX could play 
a role in infection or immune response as well.
The spectrum of incident diseases associated with 
mLOY differed substantially from autosomal mCAs and 
mLOX. As mLOY is the most commonly observed mCA 
in men, the UK Biobank male population had increased 
power for detecting incident disease associations with 
mLOY. Despite this improved power for detecting asso-
ciations, we observed a paucity of evidence for incident 
disease associations with mLOY. It is notable that previ-
ously published mLOY associations were not confirmed 
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after Bonferroni correction (p < 4.39 ×  10–5), such as solid 
tumor risk [13, 26], Alzheimer’s disease [7], major cardio-
vascular events [18], age-related macular degeneration 
[17], autoimmune thyroiditis [39], primary biliary cirrho-
sis [24], testicular germ cell tumor [32], and abdominal 
aortic aneurysm [45]. While these findings could indicate 
limited evidence for associations with mLOY and inci-
dence of these diseases in the UK Biobank male popula-
tion, we noted the multiple testing correction threshold 
for significance was stringent and that the generally 
healthy participant pool in the UK Biobank male partici-
pants [15] may not have been ideal to investigate associa-
tions with these disease outcomes.
To further compare our mLOY findings with those pre-
viously reported, we restricted our analyses to male par-
ticipants over the age of 65 years old but did not observe 
evidence for associations of mLOY with Alzheimer’s dis-
ease, major cardiovascular events or age-related macular 
degeneration (Additional file 1: Table S9). Our detection 
method also included phase-based data to increase sensi-
tivity to detect lower frequency mLOY clones, which may 
have reduced the effect size of associations with disease 
risk. To further explore the impact of clonal frequency 
on disease risk, we performed sensitivity analyses using 
different cell fraction thresholds (0.03, 0.1, and 0.2), but 
did not observe evidence for mLOY associations with 
incidence of closely matching disease codes of the previ-
ously reported diseases above passing phenome-wide sig-
nificance level (Additional file 1: Table S10). Finally, our 
modeling approach investigated incident disease risk in 
which some previously reported mLOY associations were 
for prevalent disease and adjusted for an expanded list of 
confounders in an attempt to as comprehensively as pos-
sible rule out potential biases. For example, we derived 
and adjusted for more granular smoking covariates (25 
Fig. 2 Manhattan plots of ATC medication codes (level 3) and mCAs 
in the UK Biobank. All associations are adjusted for age,  age2, detailed 
25‑level smoking, and sex (only for autosomal mCA analyses). 
Colors are used to separate medications in different ATC level 1 
categories. The red line represents the Bonferroni‑corrected, PheWAS 
significance level (0.05/number of medication codes tested). The 
blue dashed line represents the minimum, suggestive threshold (1/
number of medication codes tested). A maximum of the ten most 
significant medication codes above the suggestive threshold are 
labeled. PheWAS associations are reported for: a Autosomal mCAs, 
169 medication codes tested (PheWAS significance: p < 2.96 ×  10–4, 
suggestive threshold: 5.92 ×  10–3); L01X Other antineoplastic agents. 
b mLOX, 164 medication codes tested (PheWAS significance level 
p < 3.05 ×  10–4, suggestive threshold: 6.10 ×  10–3); D03B Enzymes for 
treatment of wounds and ulcers and M09A Other drugs for disorders 
of the musculo‑skeletal system. c mLOY, 153 medication codes tested 
(PheWAS significance level p < 3.27 ×  10–4, suggestive threshold: 
6.54 ×  10–3); A10A Insulins and analogues, A10B Blood glucose 
lowering drugs, excluding insulin, A11C Vitamin A and D, including 
combinations of the two, C02C Antiandrenergic agents, peripherally 
acting, C07A Beta blocking agents, C08C Selective calcium channel 
blockers with mainly vascular effects, C10A Lipid modifying agents, 
plain, M04A Antigout preparations, R01A Decongestants and other 
nasal preparations for topical use, and S01X Other opththalmologicals
▸
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levels, Additional file 1: Table S11) as well as modeled age 
with both age and  age2 to account for potential non-lin-
ear relationships with age (Additional file 1: Tables S12).
Interestingly, we observed negative associations 
between mLOY and several metabolic-related dis-
eases. We performed a series of exploratory analyses 
to investigate these protective associations further and 
found that adjustment for BMI substantially attenu-
ated many of these associations; however, risk for pri-
mary hypertension and retinal diseases associated with 
metabolic syndrome remained statistically significant. 
MR analyses using previously reported mLOY variants 
discovered by GWAS [46] added additional support-
ing evidence to confirm the associations with primary 
hypertension and retinal diseases. While it is reassur-
ing that the association between retinal diseases and 
mLOY were confirmed in an MR analysis, we note that 
the mLOY discovery GWAS and this PheWAS contain 
sample overlap which could result in bias of the MR 
results toward the observed PheWAS result. Biologic 
mechanisms linking mLOY with hypertension and reti-
nal diseases are unclear and future studies in independ-
ent populations are needed to confirm these observed 
relationships.
In our PheWAS, we compared three models with 
respect to smoking adjustment: (1) no smoking adjust-
ment, (2) adjusting for 3 smoking categories (never, 
former, and current), and (3) with a 25-level detailed 
smoking adjustment. The results in Additional file  1: 
Table S11 demonstrates that some observed associations 
between mLOY and diseases using models that did not 
carefully adjust for smoking behavior are due to residual 
confounding, for example some behavioral outcomes 
were completely confounded by smoking. Similarly, we 
also ran models further examining the impact of age 
adjustment. We ran the following models: (1) unadjusted 
for age, (2) only adjusting for linear age, and (3) adjust-
ing for both a linear and squared age term. Results with 
no adjustment for age demonstrated a host of spurious 
associations due to confounding by age (Additional file 1: 
Table  S12). While linear age adjustment removed sev-
eral of these spurious findings, a few associations such as 
mental and behavioral disorders due to opioids, arthro-
sis, and polyuria remained nominally significant indi-
cating evidence of residual confounding, perhaps due to 
age. Our results suggest that including both a linear and 
squared term for age adjustment resulted in robust sta-
tistical adjustment for potential confounding due to age.
We conducted exploratory analyses that included 
prevalent disease. While we identified several poten-
tial associations between prevalent disease and mCAs, 
the incident disease associations did not always support 
these findings. In addition, as the timing of prevalent 
disease diagnosis is unknown relative to the onset of 
mosaicism, it is not possible to time the relationship 
between disease and detectible mCA in the UK Biobank 
(i.e., the order could not be conclusively defined for dis-
eases). We included preliminary results from a PheWAS 
of prevalent conditions as exploratory analyses for 
hypothesis generation and initial evidence for designing 
future investigations. We highlighted similarities across 
autosomal and sex chromosome mosaicism, but recom-
mend caution be taken in the interpretation of these find-
ings and stress the critical need for further replication in 
independent datasets.
Likewise, we performed PheWAS on medication use, 
but it is difficult to separate the relationship between 
medications and diagnoses in these results. For example, 
someone with a diabetes diagnosis is likely to be taking a 
diabetes medication such as metformin. While the mech-
anism of metformin is still being studied, it is possible 
that metformin-induced inhibition of gluconeogenesis 
and the mTOR pathway [35, 38] could have impacts on 
mCA clonal expansion [10, 47].
There are limitations of our study that should be taken 
into account when interpreting the associations reported 
herein between mCAs and diseases. First, although the 
date of diagnosis provides a certain level of temporality 
between mosaic events and diseases, we are unaware of 
the time period when initial symptoms and onset of dis-
eases occurred. The onset of disease might predate the 
onset of mosaicism even though the diagnoses occurred 
much later. Second, we chose the first occurrence of 
each disease as a defining marker of onset. For diseases 
or treatments that are ongoing or chronically reoccur, 
factoring in multiple episodes of that particular disease 
might further increase the power to detect associations. 
Third, there may be some inaccuracies or underreport-
ing in the first occurrence data in the UK Biobank due to 
(1) the primary care data is still an interim release with 
~ 45% of the participants available, (2) the completeness 
of inpatient data varies by geographical location with 
England dating back to 1997, Wales to 1998, and Scot-
land to 1981, and (3) self-report information from partic-
ipants are susceptible to inaccuracies and biases. Finally, 
conditions which do not result in primary care or inpa-
tient admissions are inevitably missing and not captured 
in the analyses.
Conclusion
In the current investigation, we report evidence for a 
broad spectrum of associations between mCAs and 
first occurrence of diseases that varies by type of mCA 
and highlight the critical importance of careful covari-
ate adjustment to minimize confounding. Our findings 
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suggest mCAs could be linked to a spectrum of health 
outcomes and as such future more focused studies are 
needed to identify important etiologic relationships 
with potential clinical utility for assessment of disease 
risk.
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